This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through December 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Health Care ETFs Outperforming: Will the Rally Last?
by Sanghamitra Saha
Health care ETFs are defensive ones, which helped those to shine amid market doldrums.
Biotech ETFs in Focus on String of Q2 Earnings Beat
by Sanghamitra Saha
Biotech ETFs draw attention post impressive Q2 results.
What Investors Need to Know about Biotech ETFs
by Neena Mishra
Smaller biotech stocks are outperforming this year; learn more about biotech ETFs best positioned to benefit
Biotech ETFs Surge on Biogen's Positive Drug Trial Result
by Sweta Killa
Biotech ETFs surge on Biogen's encouraging Phase 2 clinical study data for Alzheimer???s treatment.
Why Biotech Stocks Rallied on Biogen's Alzheimer's Test
by Ryan McQueeney
Several major biotech stocks rallied on Friday after Biogen (BIIB) reported positive results from a Phase 2 study of its Ban2401 therapy, which seeks to reduce toxic amyloid proteins associated with cognitive decline and Alzheimer's disease.
Sarepta Pharma Pushes Two Biotech ETFs to New Highs
by Sweta Killa
The encouraging early trial results for a gene therapy for Duchenne muscular dystrophy pushed Sarepta Therapeutics and few biotech ETFs to new highs.
Should You Invest in the PowerShares Dynamic Biotechnology & Genome Portfolio (PBE)?
by Sweta Killa
Sector ETF report for PBE
Why These Small Cap Biotech ETFs are Soaring
by Neena Mishra
These biotech ETFs have surged this year thanks mainly to tax reform, rising M&A and positive regulatory backdrop.
Is PowerShares Dynamic Biotechnology & Genome Portfolio (PBE) a Hot ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PBE
Here's an ETF to Invest in Immunotherapy--the Game Changing Cancer Treatment
by Neena Mishra
CNCR ETF is up about 30% this year; here is what investors need to know about immunotherapy and the ETF (CNCR, IBB).
Stock Market News for March 5, 2018
by Zacks Equity Research
Healthy rise in healthcare shares helped the S&P 500 and the Nasdaq finish in the positive territory on Friday
Biotech ETFs Head to Head: XBI vs. IBB.
by Zacks Equity Research
Head-to-head comparison of two Biotech ETFs, XBI and IBB.
3 ETFs to Watch on Biotech Earnings
by Zacks Equity Research
Major Biotech companies report mixed Q4 results.
Rush for Marijuana ETFs Getting Stronger
by Sanghamitra Saha
Teucrium plans for an Emerging Medical Agriculture Index Fund. Does this hint at a marijuana ETF?
Value Biotech ETFs to Buy Now
by Sanghamitra Saha
A few reasons why you should buy value biotech ETFs for 2018
Biotech ETFs: What Lies Ahead?
by Zacks Equity Research
It's been a good year for biotech ETFs, can the rally continue?
3 ETFs to Watch on Biotech Earnings
by Zacks Equity Research
Major Biotech companies report mixed Q3 results.
Should You Keep Your Portfolio Healthy with Biotech ETFs?
by Sanghamitra Saha
Biotech ETFs are riding high on research and developments and FDA approvals.
Biotech ETFs Soar on Gilead-Kite Deal
by Sanghamitra Saha
Gilead Sciences boosted the biotech ETF world on August 28 by announcing the buyout news of Kite Pharma.
3 ETFs to Watch Out for on Biotech Earnings
by Zacks Equity Research
Major players in the biotech space reported their second quarter 2017 results.
Can Biotech ETFs Continue to Surge Higher?
by Zacks Equity Research
There are several reasons to be positive on biotech stocks and ETFs for the rest of the year.
Just the Facts, Ma'am: July Strategy Update
by John Blank
Summer picks for the taking.
Forget Big Tech, Biotech ETFs are Soaring Higher
by Neena Mishra
Biotech stocks are surging of late; we discuss the reasons behind the rebound and highlight the best performing ETFs.